表紙
市場調查報告書
商品編碼
999263

慢性B型肝炎 (CHB):流行病學的預測 (到2029年)

Chronic Hepatitis B (CHB) - Epidemiology Forecast to 2029

出版日期: | 出版商: GlobalData | 英文 52 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球主要9個國家慢性B型肝炎 (CHB)的已受診的患病人數,2019年記錄了1777萬5652人。今後預計以0.20%的年度成長率 (AGR) 增加,至2029年達到1813萬3860人。在各國中,中國佔整體90%。患病人數增加的主要原因,是人口增加和高齡化的發展,疾病持續一生的特徵,來自嬰兒期錯過的疫苗接種計劃的高風險國的移民流入等。

本報告提供全球主要9個國家 (9MM:美國,法國,德國,義大利,西班牙,英國,日本,巴西,中國) 的慢性B型肝炎(CHB)的發病情形與今後預測相關分析,疾病的特徵和目前患病者的發病情形,今後10年的患病人數趨勢預測,男女、各年齡、各患者的狀態、並存症的各類型等詳細趨勢等調查。

目錄

第1章 目錄

第2章 慢性B型肝炎:摘要整理

第3章 流行病學

  • 疾病的背景情況
  • 危險因素與並存症
  • 全球過去趨勢
  • 預測手法
    • 資訊來源
    • 預測的前提條件與方法
  • CHB的流行病學的預測 (2019年∼2029年)
    • CHB的已受診患病人數
    • CHB的已受診患病人數:各年齡
    • CHB的已受診患病人數:男女
    • CHB的已受診患病人數:各HBeAg的狀態
    • CHB的已受診患病人數:HBV DNA的各等級
    • CHB的已受診患病人數:ALT的各等級
    • CHB的已受診患病人數:肝硬化的各類型
  • 討論
    • 流行病學的預測的考察
    • 新型冠狀病毒感染疾病 (COVID-19)的影響
    • 分析的限制
    • 分析的優勢

第4章 附錄

目錄
Product Code: GDHCER268-21

Hepatitis B is a liver disease caused by the hepatitis B virus (HBV). Hepatitis B is transmitted from person to person through blood, semen, and other body fluids (CDC, 2020; Mayo Clinic, 2020). Hepatitis B is a vaccine-preventable disease, but there is no cure if you have the disease. Chronic hepatitis B (CHB) occurs when the immune system cannot fight the infection and it remains in the body for six months or longer. CHB can be a life-threatening disease, and it is a major global health concern. Not all people with the infection will be symptomatic. In some people, CHB can develop into cirrhosis or liver cancer.

GlobalData epidemiologists used age- and sex-specific diagnosed prevalence rates to forecast the diagnosed prevalent cases. GlobalData epidemiologists applied country-specific diagnosed prevalence rates of CHB, wherever available, to each country's population to obtain the number of estimated diagnosed prevalent cases. Diagnosed prevalent cases were also segmented by e-antigen status, HBV DNA level, ALT level, type of liver cirrhosis and co-infection with HIV or HCV.

The following data describes epidemiology of CHB cases. In 2019, the 9MM had 17,775,652 diagnosed prevalent cases of CHB. This is expected to increase to 18,133,860 cases by 2029, at an Annual Growth Rate (AGR) of 0.20%. The increase is driven by changes in the in the underlying population structure such as aging and population growth in the 9MM. In 2019, in each of the 9MM except China, the majority of diagnosed prevalent cases of CHB were negative for e-antigen. In the 9MM, China accounted approximately 90% of all diagnosed prevalent cases of CHB. The stagnant prevalence rate in the 9MM, is primarily due to the lifetime nature of the condition and to a large proportion of cases in the 9MM occurring in migrants from higher-risk countries who have missed the vaccination program in infancy.

Scope

  • The Chronic Hepatitis B Epidemiology Report provides an overview of the risk factors and global trends of CHB in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, and Japan, Brazil and China).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in all across the 9MM: diagnosed prevalent cases of CHB by age and sex; diagnosed prevalent cases of CHB by e-antigen status; diagnosed prevalent cases of CHB by HBV DNA level; diagnosed prevalent cases of CHB cases by ALT level; diagnosed prevalent cases of CHB by type of liver cirrhosis; diagnosed prevalent cases of CHB by co-infection with HIV or HCV.
  • The CHB epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to Buy

The CHB Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global CHB market.
  • Quantify patient populations in the global CHB market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CHB therapeutics in each of the markets covered.
  • Understand magnitude of CHB population by e-antigen status, HBV DNA level, ALT level, type of liver cirrhosis and co-infection with HIV or HCV.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Chronic Hepatitis B: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for CHB (2019-2029)
    • 3.5.1 Diagnosed Prevalent Cases of CHB
    • 3.5.2 Age-Specific Diagnosed Prevalent Cases of CHB
    • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of CHB
    • 3.5.4 Diagnosed Prevalent Cases of CHB by HBeAg Status
    • 3.5.5 Diagnosed Prevalent Cases of CHB by HBV DNA Level
    • 3.5.6 Diagnosed Prevalent Cases of CHB by ALT Level
    • 3.5.7 Diagnosed Prevalent Cases of CHB by Type of Liver Cirrhosis
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 COVID-19 Impacts
    • 3.6.3 Limitations of Analysis
    • 3.6.4 Strengths of Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 Primary Research - Prescriber Survey
  • 4.3 About the Authors
    • 4.3.1 Epidemiologist
    • 4.3.2 Reviewers
    • 4.3.3 Global Director of Therapy Analysis and Epidemiology
    • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.4 About GlobalData
  • 4.5 Contact Us
  • 4.6 Disclaimer

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for Chronic Hepatitis B
  • Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: 9MM, Diagnosed Prevalent Cases of CHB, Both Sexes, All Ages, 2019 and 2029.
  • Figure 2: 9MM, Diagnosed Prevalence of CHB (%), Both Sexes, All Ages, 2009-2019.
  • Figure 3: 9MM, Sources Used and Not Used for Diagnosed Prevalence of CHB (%)
  • Figure 4: 9MM, Sources Used for Diagnosed Prevalent Cases of CHB by HBeAg Status (N)
  • Figure 5: 9MM, Sources Used and Not Used for Diagnosed Prevalent Cases of CHB by HBV DNA Level (N)
  • Figure 6: 9MM, Sources Used for Diagnosed Prevalent Cases of CHB by ALT Level (N)
  • Figure 7: 9MM, Sources Used for Diagnosed Prevalent Cases of CHB by Type of Liver Cirrhosis (N)
  • Figure 8: 9MM, Diagnosed Prevalent Cases of CHB, Men and Women, All Ages, N, 2019
  • Figure 9: 9MM, Age-Specific Diagnosed Prevalent Cases of CHB, 9MM, Men and Women, All Ages, N, 2019
  • Figure 10: 9MM, Sex-Specific Diagnosed Prevalent Cases of CHB, All Ages, N, 2019
  • Figure 11: 9MM, Diagnosed Prevalent Cases of CHB by HBeAg Status, Men and Women, All Ages, N, 2019
  • Figure 12: 9MM, Diagnosed Prevalent Cases of CHB by HBV DNA Level, Men and Women, All Ages, N, 2019
  • Figure 13: 9MM, Diagnosed Prevalent Cases of CHB by ALT Level, Men and Women, All Ages, N, 2019
  • Figure 14: 9MM, Diagnosed Prevalent Cases of CHB by Type of Liver Cirrhosis, Men and Women, All Ages, N, 2019